Virological and Immunological Status of the People Living with HIV/AIDS Undergoing ART Treatment in Nepal

Figure 6

Virological and immunological failure rates with different ART regimes. The blue bar shows the percentage of patients treated with given regimens and having reported to have CD4⁺ T cell counts less than 350 cells/cumm. CD4⁺ T cell count less than 350 cells/cumm was considered borderline to determine eligibility for starting the ART before implementation of the new consolidated guideline for treatment of HIV 2013. Red bar shows the number of patients treated with the given regimen shown to have viral load more than 1000 copies/mL. EFV: Efavirenz, 3TC: Lamivudine, NVP: Nevirapine, AZT: Zidovudine, TDF: Tenofovir, and ABC: Abacavir.